Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis

  title={Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis},
  author={Mark Rep Sanford},
  • M. Sanford
  • Published 26 July 2014
  • Medicine, Psychology
  • Drugs
Fingolimod (Gilenya®) is an orally administered disease modifying agent (DMA) for use in relapsing-remitting multiple sclerosis (RRMS). In placebo-controlled trials in patients with RRMS with active disease, fingolimod 0.5 mg/day significantly reduced the annualized relapse rate (ARR) by approximately one-half over 2-year trial periods. It also significantly increased the proportion of patients with no disability progression, reduced deterioration from baseline in the Extended Disability Status… 

Long-term outcome in multiple sclerosis patients treated with fingolimod.

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study

The analysis of patients who received fingolimod in routine clinical practice confirmed adequate efficacy and safety, even for long-term treatment, and confirmed the positive benefit/risk balance with fingolIMod in real-world clinical practice setting.

Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.

The potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various DMTs are outlined.

Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing–remitting multiple sclerosis: A clinical trial study

A significant reduction in the level of ALT and AST, reduction of main pathogenic factors in MS containing malondialdehyde, and also a significant rise in total antioxidant capacity, and total thiol groups in the serum of patients treated with silymarin as compared with the placebo group.

The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary

Fingolimod has proven to be a well-tolerated DMT that has sustained its manageable safety profile, high efficacy, and positive benefit/risk ratio for up to 5 years in a real-life setting in Hungary.

Optimizing therapy early in multiple sclerosis: An evidence-based view.

Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients

An overview on what is presently known about body fluid markers for the prediction of response to the currently approved MS therapeutics and the potential use of biomarkers with regard to drug-induced adverse events is provided.



A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings.

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

This study demonstrated the clinical efficacy of fingolimod for the first time in Japanese patients with MS, consistent with the established effects of fingolinium (Gd) in Caucasian patients.

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Fingolimod was generally well tolerated in these trials of up to 2 years' duration, with most adverse events being manageable and of mild to moderate severity; there were two deaths from opportunistic infections, albeit these occurred with fingolIMod 1.25 mg/day (higher than the recommended dosage).

Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States

Fingolimod use is not likely to be cost-effective compared to IFN beta-1a unless fingolimmod cost falls below $3476 per month or a higher than normal willingness-to-pay threshold is accepted by decision-makers.

Early tolerability and safety of fingolimod in clinical practice

Fingolimod Treatment Increases the Proportion of Patients Who Are Free from Disease Activity in Multiple Sclerosis Compared to IFN-b1a: Results from a Phase 3, Active-Controlled Study (TRANSFORMS) (PD5.006)

Fingolimod therapy significantly increased the proportion of patients with MS who were free of disease activity compared with IFN beta-1a IM over 12 months.